FDA Clears MiniMed Flex, a New Automated Insulin Device

MiniMed announced the FDA clearance of MiniMed Flex, the company's smallest insulin pump to date and its first to feature a smartphone-controlled and screenless design. This next-generation device is approximately half the size of the previous MiniMed 780G system and is designed to fit discreetly into everyday life, roughly the size of 2 stacked insulin vials.¹

For pharmacists, this launch represents a significant milestone in diabetes technology, as the device is powered by the SmartGuard adaptive algorithm with meal detection technology, which has demonstrated clinical performance exceeding global time in range recommendations. The MiniMed Flex is cleared for individuals 7 years and older with type 1 diabetes and for adults with insulin-requiring type 2 diabetes.

The introduction of such discreet technology addresses the growing need for lifestyle-friendly management tools that reduce the daily burden of chronic illness. Clinical experts note that the combination of a screenless form factor and advanced automation allows the technology to work quietly in the background, potentially improving patient consistency and confidence.

At launch, the system will support a 300-unit insulin reservoir and maintain compatibility with the company's newest sensor portfolio, including the Simplera Sync and the Abbott-made Instinct sensor. Furthermore, the system works with extended infusion sets that offer up to 7 days of wear, which can result in up to 96% fewer injections compared to traditional therapy.

However, the success of these advanced automated insulin delivery (AID) systems often depends on the therapeutic relationship between the patient and the pharmacist. Although hardware like the MiniMed Flex can automate dosing, research suggests that the language used during pharmacy encounters is a critical factor in patient outcomes. Stigmatizing labels such as "noncompliant" or "uncontrolled" remain prevalent in clinical practice and can lead to increased psychological distress, higher A_1C values, and a decreased willingness for patients to share real-world barriers.²

Pharmacists are increasingly encouraged to adopt person-first, strengths-based phrasing, such as "medication taking" instead of "compliance" and "blood glucose targets" instead of "control," to build the trust necessary for effective long-term management.

“One of our biggest roles as a pharmacist on that care team is going to be education,” Jennifer Griffin, PharmD, clinical pharmacist at Harps Food Stores Inc, said.³ “We have so much education when it comes to these medications and insulin management, so it's important that pharmacists are empowered to speak up and share that expertise, and this can look like educating patients on proper injection technique or how to manage their hypoglycemia.”

Beyond communication, the role of the pharmacist is evolving from traditional dispensing to a clinical, technology-focused partnership. New implementation models, such as the remote hub model explored in the ACCESS-AID study, demonstrate how pharmacists can be upskilled through mentored training to manage complex pumps, continuous glucose monitors, and algorithms. By providing structured support and daily data reviews during the critical first 12 weeks of technology adoption, pharmacists can help resolve common individual-level barriers such as alarm fatigue, adhesive-related skin irritation, and the logistical friction of navigating supply chains.⁴

“Patients may see that their blood sugar is high, so they will self-titrate,” Griffin said.³ “Whenever a patient is first started on insulin therapy, I want them to know how dangerous insulin can be if used incorrectly, but I don't want them to be afraid of it, only cautious with it.”

By utilizing prioritization scores that favor patients with the highest expected marginal benefit—such as those with high hemoglobin A_1c levels or those in rural communities—pharmacists can help ensure that innovations like the MiniMed Flex reach those who have historically faced geographic or systemic barriers to care.¹

READ MORE: Insulin Management Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. MiniMed announces FDA clearance of MiniMed Flex, the company's smallest insulin pump featuring its first smartphone-controlled design. News release. MiniMed. March 18, 2026. Accessed March 18, 2026. https://news.minimed.com/2026-03-18-MiniMed-Announces-FDA-Clearance-of-MiniMed-Flex-TM-,-the-Companys-Smallest-Insulin-Pump-Featuring-Its-First-Smartphone-Controlled-Design

2. Gallagher A. Language Used for Insulin Management Impacts Patients’ Diabetes Outcomes. Drug Topics. March 10, 2026. Accessed March 18, 2026. https://www.drugtopics.com/view/language-used-for-insulin-management-impacts-patients-diabetes-outcomes

3. Gallagher A. Q&A: Community Pharmacists Educate Patients on Safe Insulin Use. Drug Topics. December 20, 2025. Accessed March 18, 2026. https://www.drugtopics.com/view/q-a-community-pharmacists-educate-patients-on-safe-insulin-use

4. Gallagher A. Pharmacists Help Resolve Barriers in Automated Insulin Delivery for Patients With Type 1 Diabetes. Drug Topics. March 14, 2026. Accessed March 18, 2026. https://www.drugtopics.com/view/pharmacists-help-resolve-barriers-in-automated-insulin-delivery-for-patients-with-type-1-diabetes